These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8725999)

  • 1. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication.
    Deminie CA; Bechtold CM; Stock D; Alam M; Djang F; Balch AH; Chou TC; Prichard M; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1346-51. PubMed ID: 8725999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
    Patick AK; Boritzki TJ; Bloom LA
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2159-64. PubMed ID: 9333041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
    Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
    Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.
    Naeger LK; Margot NA; Miller MD
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2179-84. PubMed ID: 12069972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells.
    Carter MM; Torres SM; Cook DL; McCash CL; Yu M; Walker VE; Walker DM
    Environ Mol Mutagen; 2007; 48(3-4):239-47. PubMed ID: 17358029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
    Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
    Brennan TM; Taylor DL; Bridges CG; Leyda JP; Tyms AS
    Antiviral Res; 1995 Mar; 26(2):173-87. PubMed ID: 7541619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
    Merrill DP; Moonis M; Chou TC; Hirsch MS
    J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
    Robinson BS; Riccardi KA; Gong YF; Guo Q; Stock DA; Blair WS; Terry BJ; Deminie CA; Djang F; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2093-9. PubMed ID: 10898681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
    Xu G; Micklatcher M; Silvestri MA; Hartman TL; Burrier J; Osterling MC; Wargo H; Turpin JA; Buckheit RW; Cushman M
    J Med Chem; 2001 Nov; 44(24):4092-113. PubMed ID: 11708913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in anti-HIV chemotherapy.
    De Clercq E
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP; Nandy P; Avramis VI
    In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Which is the strategy? The latest in the use of antiretrovirals].
    Agosto M
    Sidahora; 1995; ():33-4. PubMed ID: 11363205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors.
    Contreras-Galindo R; Dube D; Fujinaga K; Kaplan MH; Markovitz DM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in anti-HIV chemotherapy.
    De Clercq E
    Curr Med Chem; 2001 Nov; 8(13):1543-72. PubMed ID: 11562282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
    Connell EV; Hsu MC; Richman DD
    Antimicrob Agents Chemother; 1994 Feb; 38(2):348-52. PubMed ID: 7514858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.
    Hoggard PG; Sales SD; Kewn S; Sunderland D; Khoo SH; Hart CA; Back DJ
    Antivir Chem Chemother; 2000 Nov; 11(6):353-8. PubMed ID: 11227992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART.
    Paolucci S; Baldanti F; Maserati R; Castelli F; Suter F; Maggiolo F; Pan A; Gerna G
    Antiviral Res; 2000 Feb; 45(2):101-14. PubMed ID: 10809019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.